Flynn James E 13D and 13G filings for Deciphera Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 5:32 pm Purchase |
2023-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 5,788,024 7.190% |
1,160,714 (+25.08%) |
Filing |
| 2023-03-22 4:17 pm Purchase |
2023-03-13 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 4,627,310 6.090% |
2,278,082 (+96.97%) |
Filing |
| 2023-02-10 09:42 am Sale |
2022-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 2,349,228 3.480% |
-3,231,228 (-57.90%) |
Filing |
| 2022-02-11 4:10 pm Purchase |
2021-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 5,580,456 9.540% |
1,376,556 (+32.74%) |
Filing |
| 2021-11-10 4:59 pm Purchase |
2021-11-05 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 4,203,900 7.190% |
4,203,900 (New Position) |
Filing |